Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to Odefsey in Virologically Suppressed HIV-1
NCT02345252Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of emtricitabine + rilpivirine + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started Jan 2015; status: completed.
02
Drugs
emtricitabine + rilpivirine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02345252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02345252.